1. 3. Committee for Proprietary Medicinal Products (CPMP). The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools (CPMP/BWP/390/97). Addendum to note for guidance on plasma derived products (CPMP/BWP/269/95). London, 1998 .